SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-19-119744
Filing Date
2019-04-25
Accepted
2019-04-25 16:28:56
Documents
7
Effectiveness Date
2019-04-25

Document Format Files

Seq Description Document Type Size
1 DEFA14A d686406ddefa14a.htm DEFA14A 33321
2 GRAPHIC g686406g05e15.jpg GRAPHIC 23408
3 GRAPHIC g686406g16q56.jpg GRAPHIC 13701
4 GRAPHIC g686406g25y45.jpg GRAPHIC 37689
5 GRAPHIC g686406g62d05.jpg GRAPHIC 24728
6 GRAPHIC g686406g76c99.jpg GRAPHIC 32714
7 GRAPHIC g686406g87n84.jpg GRAPHIC 13084
  Complete submission text file 0001193125-19-119744.txt   235022
Mailing Address 100 TECHNOLOGY SQUARE 5TH FLOOR CAMBRIDGE MA 02139
Business Address 100 TECHNOLOGY SQUARE 5TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Magenta Therapeutics, Inc. (Filer) CIK: 0001690585 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38541 | Film No.: 19767824
SIC: 2834 Pharmaceutical Preparations